Equities
Health CareHealth Care Equipment & Services
  • Price (USD)17.73
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-8.60%
  • Beta1.2983
Data delayed at least 15 minutes.
More ▼

Profile data is unavailable for this security.

About the company

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.

  • Revenue in EUR (TTM)496.16m
  • Net income in EUR50.81m
  • Incorporated2007
  • Employees2.49k
  • Location
    Fagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
  • Phone+32 80012880
  • Fax+32 92162491
  • Websitehttps://fagron.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FAGR:BRU since
announced
Transaction
value
Central De Drogas SA De CVAnnounced13 May 201913 May 2019Announced-4.80%24.22m
Dr. Kulich Pharma sroDeal completed13 May 201913 May 2019Deal completed-4.80%6.18m
Data delayed at least 15 minutes, as of Sep 20 2019 16:35 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.